Henan Cancer Hospital: clinical-trial pipeline
Henan Cancer Hospital is the sponsor of 234 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 104 are not yet finished and 3 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Trials by phase
| Phase | Trials |
|---|---|
| Phase 2 | 115 |
| Not applicable | 70 |
| Phase 1 | 17 |
| Phase 1/2 | 14 |
| Phase 3 | 11 |
| Phase 4 | 4 |
| Early phase 1 | 2 |
| Phase 2/3 | 1 |
Trials by status
| Status | Trials |
|---|---|
| Unknown | 103 |
| Recruiting | 54 |
| Not yet recruiting | 44 |
| Completed | 17 |
| Active, not recruiting | 6 |
| Terminated | 5 |
| Withdrawn or not authorised | 4 |
| Suspended or halted | 1 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 211 |
| Gastroenterology and liver | 15 |
| Musculoskeletal | 5 |
| Dermatology | 2 |
| Haematology | 2 |
| Nephrology and urology | 2 |
| Immunology and rheumatology | 1 |
| Metabolic and endocrine (diabetes, obesity) | 1 |
| Psychiatry and mental health | 1 |
| Women's health and obstetrics | 1 |
Countries
| Country | Trials |
|---|---|
| China | 189 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-22 | New trial posted | Exploring Curative Model for Advanced Breast Cancer: a Single-center, Prospective Phase I… |
| 2026-09-14 | New trial posted | Trastuzumab Combined With Retlirafusp Alfa in Treating HER2（Human Epidermal Growth Factor… |
| 2026-09-03 | New trial posted | Evaluating Safety ,Tolerability, Pharmacokinetic,Efficacy of WJ01024 or WJ01024 Combined… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT07037537 | Evaluation of the Effectiveness and Safety of Laparoscopic Assisted Mastectomy With Preservation of Nipple an… | Not applicable | Recruiting | China |
| NCT04891016 | Toripalimab Plus FLOT in Locally Advanced Gastric Cancer | Phase 2 | Recruiting | China |
| NCT07559786 | A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Li… | Phase 2 | Recruiting | China |
| NCT07244016 | Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment… | Not applicable | Recruiting | China |
| NCT05063136 | Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer | Phase 3 | Recruiting | China |
| NCT05495152 | Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma | Phase 3 | Recruiting | China |
| NCT05177068 | Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer | Phase 2 | Active, not recruiting | China |
| NCT05911958 | A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer | Phase 2 | Recruiting | China |
| NCT06819319 | SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer | Phase 2 | Not yet recruiting | |
| NCT06817525 | Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC | Phase 2 | Recruiting | China |
| NCT07706933 | Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast Cancer | Not applicable | Not yet recruiting | |
| NCT06774222 | A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Po… | Phase 2 | Recruiting | China |
| NCT04263935 | Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis i… | Not applicable | Recruiting | China |
| NCT05918328 | Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC | Phase 2 | Recruiting | China |
| NCT07778056 | Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Immunochemotherapy for Resectable Esophageal Cancer: A Targe… | Not applicable | Not yet recruiting | |
| NCT06256627 | The Maintenance Treatment of "ITIVA" in AML Patients | Not applicable | Recruiting | China |
| NCT05617846 | Application of Antiosteoporosis Therapy in Osteolysis | Not applicable | Not yet recruiting | China |
| NCT07264569 | Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001 | Phase 1/2 | Recruiting | China |
| NCT06685354 | Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study | Phase 2 | Not yet recruiting | China |
| NCT06293014 | TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer | Phase 2 | Recruiting | China |
| NCT06394661 | Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer | Phase 2 | Active, not recruiting | China |
| NCT06465238 | Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC | Phase 2 | Not yet recruiting | China |
| NCT07610629 | Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesop… | Phase 2 | Not yet recruiting | China |
| NCT05377658 | AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer | Phase 2 | Recruiting | China |
| NCT05398861 | Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer | Phase 2 | Recruiting | China |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Henan Cancer Hospital clinical trials: 104 open, 12 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/henan-cancer-hospital/, data as of 2026-10-25.